Design of a potent, soluble glucokinase activator with increased pharmacokinetic half-life

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 11, 2011, Pages 3467-3470

  Pike, Kurt G ^a   Allen, Joanne V ^a   Caulkett, Peter W R ^a   Clarke, David S ^a   Donald, Craig S ^a   Fenwick, Mark L ^a   Johnson, Keith M ^a   Johnstone, Craig ^a   McKerrecher, Darren ^a   Rayner, John W ^a   Walker, Rolf P ^a   Wilson, Ingrid ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Bioavailability; GKA; GKA50; GKA60; Glucokinase activator; Type 2 diabetes; Unbound clearance

Indexed keywords

ENZYME ACTIVATOR; GLUCOKINASE ACTIVATOR; GLUCOKINASE ACTIVATOR 22; GLUCOKINASE ACTIVATOR 50; GLUCOKINASE ACTIVATOR 60; UNCLASSIFIED DRUG;

ARTICLE; DRUG DESIGN; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SOLUBILITY; DRUG STRUCTURE; HUMAN; LIPOPHILICITY; NONHUMAN;

ANIMALS; DOGS; DRUG DESIGN; ENZYME ACTIVATION; ENZYME ACTIVATORS; GLUCOKINASE; HALF-LIFE; HUMANS; HYPOGLYCEMIC AGENTS; MOLECULAR STRUCTURE; PYRIDINES; RATS; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79956067812     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.03.093     Document Type: Article

References (19)

1. M. Tadayyon, and S.A. Smith Expert Opin. Invest. Drugs 12 2003 307
2. R.C. Turner, C.A. Cull, V. Frighi, and R. Holmann J. Am. Med. Assoc. 281 1999 2005
3. F.M. Matschinsky Diabetes 51 2002 S394
4. F.M. Matschinsky, M.A. Magnuson F.M. Matschinsky, and M.A. Magnuson Frontiers in Diabetes Vol. 16 2004 Karger Basel 1 17
5. A.l. Gloyn, S. Odili, D. Zelent, C. Buettger, H.A. Castleden, A.M. Steele, A. Stride, C. Shiota, M.A. Magnuson, R. Lorini, G. d'Annunzio, C.A. Stanley, J. Kwagh, E. van Schaftingen, M. Veigha da Cunha, F. Barbetti, P. Dunten, Y. Han, J. Grimsby, R. Taub, S. Ellard, A.T. Hattersley, and F.M. Matschinsky J. Biol. Chem. 280 2005 14105
6. B. Leighton, A. Atkinson, and M.P. Coghlan Biochem. Soc. Trans. 33 2005 371
7. D. Zelent, H. Najafi, S. Odili, C. Buettger, H. Weik-Collins, C. Li, N. Doliba, J. Grimsby, and F.M. Matschinsky Biochem. Soc. Trans. 33 2005 306
8. For comprehensive reviews of GKAs see: M.C.T. Fyfe, and M.P. Procter Drugs Future 34 2009 641
9. F.M. Matschinsky Nat. Rev. Drug Disc. 8 2009 399
10. M. Coghlan, and B. Leighton Expert Opin. Invest. Drugs 17 2008 145
11. D. McKerrecher, J.V. Allen, S.S. Bowker, S. Boyd, P.W.R. Caulkett, G.S. Currie, C.D. Davies, M.L. Fenwick, H. Gaskin, E. Grange, R.B. Hargreaves, B.R. Hayter, R. James, K.M. Johnson, C. Johnstone, C.D. Jones, S. Lackie, J.W. Rayner, and R.P. Walker Bioorg. Med. Chem. Lett. 15 2005 2103
12. D. McKerrecher, J.V. Allen, P.W.R. Caulkett, C.S. Donald, M.L. Fenwick, E. Grange, K.M. Johnson, C. Johnstone, C.D. Jones, K.G. Pike, J.W. Rayner, and R.P. Walker Bioorg. Med. Chem. Lett. 16 2006 2705
13. W.L. Chiou, G. Robbiel, S.M. Chung, T.-C. Wul, and C. Mal Pharm. Res. 15 1998 1474
14. G.J. Coope, A.M. Atkinson, C. Allott, D. McKerrecher, C. Johnstone, K.G. Pike, P.C. Holme, H. Vertigan, D. Gill, M.P. Coghlan, and B. Leighton Br. J. Pharmacol. 149 2006 328
15. max. Detailed in vitro studies and assay conditions are described in: K.J. Brocklehurst, V.A. Payne, R.A. Davies, D. Carroll, H.L. Vertigan, H.J. Wightman, S. Aiston, I.D. Waddell, B. Leighton, M.P. Coghlan, and L. Agius Diabetes 53 2004 535
16. 11.
17. Rat clearance values were obtained following an IV dose of 1 mg/kg to CR-Han Wistar rats. The compounds were dosed as a solution and the clearance values are quoted in mL/min/kg.
18. C log P values were calculated using the commercially available package C log P v4.3 from BioByte Corp, 201 W. 4th St., #204 Claremont, CA 91711-4707.
19. D.A. Evans, J.L. Katz, and T.R. West Tetrahedron Lett. 39 1998 2937